Article Text

Download PDFPDF
Biomarkers in psoriasis and psoriatic arthritis
  1. Federica Villanova1,2,
  2. Paola Di Meglio3,
  3. Frank O Nestle1,2
  1. 1St John's Institute of Dermatology, King's College London, London, UK
  2. 2NIHR GSTT/KCL Comprehensive Biomedical Research Centre, Guy's and St Thomas’ NHS Foundation Trust, London, UK
  3. 3Department of Molecular Immunology, MRC National Institute for Medical Research, London, UK
  1. Correspondence to Professor Frank O Nestle, St John's Institute of Dermatology, King's College London, London SE1 9RT, UK; frank.nestle{at}


Psoriasis is a common immune-mediated disease of the skin, which associates in 20–30% of patients with psoriatic arthritis (PsA). The immunopathogenesis of both conditions is not fully understood as it is the result of a complex interaction between genetic, environmental and immunological factors. At present there is no cure for psoriasis and there are no specific markers that can accurately predict disease progression and therapeutic response. Therefore, biomarkers for disease prognosis and response to treatment are urgently needed to help clinicians with objective indications to improve patient management and outcomes. Although many efforts have been made to identify psoriasis/PsA biomarkers none of them has yet been translated into routine clinical practice. In this review we summarise the different classes of possible biomarkers explored in psoriasis and PsA so far and discuss novel strategies for biomarker discovery.

  • Psoriatic Arthritis
  • TNF-alpha
  • Treatment
  • Inflammation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.